Bevacizumab biosimilar (Celltrion)

贝伐珠单抗生物类似药 (Celltrion)

Report date: 2022/09/29 10:22:12

Base Information

Drug NameBevacizumab biosimilar (Celltrion)
Drug Alias Name贝伐赛珠单抗生物仿制药 (Celltrion)贝伐人源化单抗生物仿制药 (Celltrion)贝伐珠单抗生物仿制药 (Celltrion)贝伐单抗生物仿制药 (Celltrion)Vegzelma +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Global Approved IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2022/08/17
Country/TerritoryUnited StatesSouth KoreaEU +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCelltrion Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelltrion Healthcare Hungary KftCelltrion IncNippon Chemiphar Co Ltd
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksN/A